← Back to Clinical Trials
Recruiting NCT07637669

NCT07637669 Olfactory Function and Model-Based Behavior in People Living With HIV and SUD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07637669
Status Recruiting
Phase —
Sponsor National Institute on Drug Abuse (NIDA)
Condition HIV
Study Type OBSERVATIONAL
Enrollment 120 participants
Start Date 2026-11-18
Primary Completion 2031-06-27

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 120 participants in total. It began in 2026-11-18 with a primary completion date of 2031-06-27.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Background: Human immunodeficiency virus (HIV) infection can affect areas of the brain that control thinking ability. These same areas of the brain also control the sense of smell. HIV infection is common in people with substance use disorder (SUD). SUD also affects thinking ability. Researchers want to learn more about the connection between the sense of smell and decision-making ability in people with HIV, SUD, or both. Objective: To test the sense of smell in people with HIV and/or SUD and how they make choices based on odors. Eligibility: People aged 18 to 65 years with any of these: (1) HIV, (2) SUD, (3) both HIV and SUD, or (4) neither SUD nor HIV. Design: Participants will have 2 visits. Each visit will last 3 to 5 hours. In visit 1, participants will have a blood draw and a saliva swab. They will answer questions about their health, sleep habits, food intake, and substance use. They will have smell tests: They will smell scented sticks and answer questions about them. They will be blindfolded for some tests. They will perform tasks on a computer. They will look at pictures and smell pleasant food odors, such as chocolate cake or pizza. Smells will be delivered using a nasal mask. Their sniffing and breathing will be measured. They may also be exposed to odor-free air. They will eat food that corresponds to one of the food odors they smelled. In visit 2, participants will do a saliva swab and a different computer task that involves odors. They will also have tests of their attention and memory. Participants may opt to have an imaging scan of the brain.

Eligibility Criteria

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: For all participants: 1. Aged 18-65 years old. Justification: prevalence of olfactory impairments increases with age; after age 53, the prevalence is 24.5 percent, increasing to 62.5 percent in people ages 80-97. 2. Ability of subject to understand and the willingness to sign a written informed consent document. For participants in the HIV+ and SUD+ and HIV+ and SUD- groups: 1\. HIV positive. For participants in the HIV+ and SUD+ and HIV- \& SUD+ groups: 1\. Current history (past 12 months) of Substance Use Disorder (SUD) or medical treatment for SUD, other than Alcohol Use Disorder (AUD), mild Cannabis Use Disorder (CUD), or Tobacco Use Disorder (TUD). Non-medical treatments for SUD will be evaluated on a case-by-case-basis by the MAI. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: For all participants: 1. History of neurological illnesses or neurosurgery including but not limited to cerebrovascular accident, Parkinson disease, Alzheimer disease, Huntington disease, central nervous system (CNS) tumor, significant head trauma with sequelae, multiple sclerosis or other demyelinating diseases, epilepsy, movement disorders. The MAI will also retain discretion to exclude based on a history of a neurological illness or trauma that may compromise data integrity. 2. History of current (past 3 months) symptomatic, more than mild DSM-5 psychiatric disorder including major affective disorder, obsessive-compulsive disorder, schizophrenia, or posttraumatic stress disorder, excluding SUD. This will be determined at the discretion of the MAI. 3. Candidates who recently (12 hours prior to a study visit) used medications and/or substances that are psychoactive or otherwise affect alertness will have to pass a clinical assessment for intoxication on the day of the study visit. Based on participant preferences and MAI/PI judgment, participants who fail the clinical assessment for intoxication will either be withdrawn or rescheduled. 4. History of clinically significant anaphylaxis, e.g., due to severe asthma or food and nonfood allergies (e.g., latex, detergents, soap, etc.). The MAI will retain discretion to exclude a participant based on this criterion. 5. Uncorrected impairments in visual acuity severe enough to affect task performance. 6. Non-English speaking. Justification: The data integrity of some of the behavioral tasks used in this study would be compromised as they have only been validated in English. 7. Pregnancy. 8. Any other condition that in the judgment of the investigators is incompatible with participation. For participants in the HIV+ and SUD- and HIV- and SUD- groups: 1. History (past 5 years) of SUD, excluding tobacco use disorder (TUD). 2. Pattern of alcohol and drug use in the past 12 months that is indicative of harmful use, loss of control over use, or physical dependence. 3. Daily alcohol or drug use (excluding caffeine and nicotine) for at least 4 continuous weeks in the past 12 months. For participants in the HIV- and SUD+ and HIV- and SUD- groups: 1\. HIV positive. For participants in the HIV- \& SUD- group: 1\. Unable to undergo MRI scanning due to certain metallic or magnetic devices or implants in the body, or claustrophobia. For the Optional MRI Segment: 1\. Unable to undergo MRI scanning due to certain metallic or magnetic devices or implants in the body, or claustrophobia.

Contact & Investigator

Central Contact

NIDA IRP Screening Team

✉ researchstudies@nida.nih.gov

📞 (800) 535-8254

Principal Investigator

Thorsten Kahnt, Ph.D.

PRINCIPAL INVESTIGATOR

National Institute on Drug Abuse (NIDA)

Frequently Asked Questions

Who can join the NCT07637669 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07637669 currently recruiting?

Yes, NCT07637669 is actively recruiting participants. Contact the research team at researchstudies@nida.nih.gov for enrollment information.

Where is the NCT07637669 trial being conducted?

This trial is being conducted at Baltimore, United States.

Who is sponsoring the NCT07637669 clinical trial?

NCT07637669 is sponsored by National Institute on Drug Abuse (NIDA). The principal investigator is Thorsten Kahnt, Ph.D. at National Institute on Drug Abuse (NIDA). The trial plans to enroll 120 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology